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Abstract
Background: The WHO treatment guidelines for the soil-transmitted helminths (STH) focus on targeting children for
the control of morbidity induced by heavy infections. However, unlike the other STHs, the majority of hookworm
infections are harboured by adults. This untreated burden may have important implications for controlling both
hookworm’s morbidity and transmission. This is particularly significant in the context of the increased interest in
investigating STH elimination strategies.
Methods: We used a deterministic STH transmission model and parameter estimates derived from field
epidemiological studies to evaluate the impact of child-targeted (2–14 year olds) versus community-wide treatment
against hookworm in terms of preventing morbidity and the timeframe for breaking transmission. Furthermore, we
investigated how mass treatment may influence the long-term programmatic costs of preventive chemotherapy for
hookworm.
Results: The model projected that a large proportion of the overall morbidity due to hookworm was unaffected by
the current child-targeted strategy. Furthermore, driving worm burdens to levels low enough to potentially break
transmission was only possible when using community-wide treatment. Due to these projected reductions in
programme duration, it was possible for community-wide treatment to generate cost savings – even if it notably
increases the annual distribution costs.
Conclusions: Community-wide treatment is notably more cost-effective for controlling hookworm’s morbidity and
transmission than the current child-targeted strategies and could even be cost-saving in many settings in the longer
term. These calculations suggest that it is not optimum to treat using the same treatment strategies as other STH.
Hookworm morbidity and transmission control require community-wide treatment.
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Background
The most common neglected tropical diseases (NTDs) are
the soil-transmitted helminths (STH) which include
Ascaris lumbricoides, Trichuris trichiura and the hook-
worms (Ancylostoma duodenale and Necator americanus).
In the 2010 Global Burden of Disease study, the hook-
worms were estimated to be responsible for over 65 % of
the total disability-adjusted life years (DALY) lost due to
STH infections [1] and, worldwide, are the second leading
cause of anaemia [2].
The current WHO guidelines focus on targeting STH
treatment to preschool-aged (Pre-SAC: 2–4 year olds) and
school-aged children (SAC: 5–14 year olds) with the ul-
timate goal to “eliminate STH as a public health problem”
in children by 2020 (though treatment of women of child-
bearing age and adults in certain high risk occupations is
also recommended where possible) [3, 4]. However, unlike
the other STH, the majority of the hookworms are har-
boured by adults (Fig. 1), as opposed to the children.
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Consequently, although the current guidelines may be ef-
fective in terms of reducing the morbidity of both Ascaris
and Trichuris (where the burden peaks in the targeted
children), they may not be as effective against hookworm.
In addition, there has recently been an increasing
interest in considering different strategies for breaking
the transmission of STH [5–7] since it is widely recog-
nised that in the absence of effective water, sanitation
and hygiene (WASH) programmes, childhood treatment
alone is unlikely to break transmission. Previous STH
modelling studies have illustrated that even in low trans-
mission settings it is not possible to eliminate hookworm
with preventative chemotherapy alone when only target-
ing children [8, 9, 10].
Expanding treatment programmes to include adults
through community-wide treatment is under consider-
ation. However, it should be noted that this would be a
major shift in STH control policy, and require an in-
crease in resources and international commitment. Con-
sequently, it is important to evaluate how cost-effective
expanding control programmes to include adults is, and
understand if it could potentially generate long term
cost-savings.
The aim of this paper is to investigate the impact, long-
term cost and cost-effectiveness of using community-wide
treatment for the control of hookworm.
Method
This analysis was performed with a fully age-structured
deterministic model of the dynamics of STH transmis-
sion (described in [8–10]), using the parameters pertain-
ing to hookworm (Additional file 1: Table S1). The
model can estimate the number of treatment rounds of
a given strategy required to theoretically achieve elimin-
ation – defined as crossing the breakpoint in transmis-
sion where infection levels settle to the equilibrium of
extinction [11].
The relative exposure of the different age groups to
the infectious reservoir defined in the model was esti-
mated using likelihood methods and the age intensity
profile of infection reported by Bradley et al. [12] (Fig. 1).
This fit is presented in Additional file 1: Figure S1.
The efficacy of albendazole (400 mg) against hookworm
(defined within the model as the proportion of worms ex-
pelled per treatment) was assumed to be 94.8 % [13]. In
the sensitivity analyses we also considered a much lower
efficacy of 64.2 % [14]. Individuals under two years of age
were considered ineligible for drug treatment.
Scenarios and output
The model was used to compare child-targeted annual
and biannual treatment (targeting Pre-SAC and SAC, 2–
14 year olds [3, 4]) to annual community-wide treatment
(targeting ≥2 year olds). Two different transmission set-
tings were explored; intermediate (R0 = 2.5), and high
(R0 = 5) – as measured by the basic reproductive num-
ber (R0) which defines the average number of female
worm offspring generated by a single female worm in
her lifespan who survive to reproductive maturity in
the absence of density-dependent or mate-availability
constraints [11]. We considered a range of different
coverage levels of adults (35–75 %).
Morbidity
The model was used to estimate the proportion of the
population at risk of morbidity. It was assumed
Fig. 1 The reported relationships between host age and mean worm burden for hookworm: The data is from the following worm expulsion
studies; India (i, Tamil Nadu (Vairavankuppam)) [40], Papua New Guinea [41], Zimbabwe [12], China [42], and India (ii, West Bengal) [43]. Panel a
illustrates the variation across the different study locations and Panel b from the different hookworm species. Children 2–14 (who are targeted for
treatment) are shaded in green and adults, (≥15 year olds (who are not targeted for treated) are shaded in red. With the assumed host demography
used within the model (from Uganda) [8], the proportion of worms harboured by adults varied between 70 and 85 % for the different profiles
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morbidity arose in those with a heavy infection, defined
by an age-specific worm burden above the standard
thresholds [15] (Table 1). These thresholds were based
on the observed relationship between infection intensity
and anaemia [16]. Though we are using a previously
established method [15, 17], it is important to acknow-
ledge that the relationships between the intensity of
STH infection and morbidity are complex and not well
understood and that this is therefore a standard simpli-
fying assumption [15, 18].
Costs
Due to the absence of cost data for community-wide
STH treatment [19], a range of relative increases in the
economic distribution cost (total per year) when using
community-wide compared to child-targeted treatment
were assumed (+50, +100, +150, and +200 % i.e. if the
full economic cost of a child-targeted programme was
US$100,000 per year, this would increase to US$150,000,
US$200,000, US$250,00 and US$300,000 per year
respectively when using community-wide treatment).
Though the relative increase in costs were not based on
any primary cost data, this wide range would capture a
very broad range of settings/scenarios. Due to the not-
able variation in reported costs of STH control pro-
grammes [19], the cost of annual child-targeted
treatment was assumed to be arbitrary – as we are only
considering the relative increase in cost/cost-effective-
ness of community-wide treatment.
As MDA programmes have substantial economies of
scale, assuming constant cost per treatment and varying
treatment coverage within a model can be highly mis-
leading [20, 21]; as the fixed costs of MDA are not
accounted for, this method can notably underestimate
the costs of treating at a lower coverage within a given
transmission setting. Due to this, we assumed a range of
different relative increases in the total cost per year of
the treatment programme when using community-wide
treatment. This reflects that the increase in cost will vary
across different settings due to a range of programmatic
factors i.e. it is possible to have a relatively inexpensive
programme with a high coverage and an expensive
programme with a low coverage.
It was assumed that after elimination was achieved,
the distribution cost stopped immediately. This reflects
that although using a community-wide treatment strat-
egy will initially increase the programmatic distribution
costs, it may generate cost savings compared to using a
child-targeted strategy for the full time horizon depend-
ing on the reduction in the required programme dur-
ation (due to the capacity to break transmission). It is
important to note that the potential programmatic costs
are only considered within the assumed time horizon for
the simulations (the potential cost savings achieved by
elimination will be greater the longer the assumed time
horizon, which is assumed to be finite in the simula-
tions, but could, in theory, be infinite).
It is also important to note that the costs were considered
from the perspective of the health care service provider
(since the costs of accessing the intervention are likely to
be negligible).
Cost-effectiveness analysis
The model was used to estimate the relative increase in
cost-effectiveness of community-wide treatment in terms
of preventing years lived with morbidity (Table 1). This
was done by comparing the incremental cost (based on
assumed percentage increase in cost of community-wide
treatment) and incremental benefit of community-wide
treatment in terms of preventing years lived with morbid-
ity in both adults and children to that of annual child-
targeted treatment, as estimated from the modelling.
Discounting
Discounting is the process of adjusting the future values
of costs to reflect the fact that society prefers to receive
benefits sooner and pay costs later. The discount rate
reflects the strength of this time reference. As recom-
mended by the WHO [22], a discount rate of 3 % per
year was applied to the costs and effects. The sensitivity
of the results to the use of different discount rates was
also explored [22].
Results
Morbidity control
The model projected that the recommended annual child-
targeted treatment (2–14 year olds) effectively reduces the
prevalence of morbidity in children (Fig. 2) – even in high
transmission settings – supporting the WHO guideline
suggestions for controlling child morbidity. For adults the
worm burden threshold for morbidity is higher than for
children (Table 1), and yet the prevalence of morbidity is
higher in adults than in children. Consequently, a large
proportion of hookworm’s overall disease burden is un-
affected by the current treatment strategy – even when
achieving a high coverage (Fig. 2). The overall impact of
Table 1 Age-specific worm burden thresholds for morbidity
[15]
Age class (years) Lower threshold Higher threshold
0–4 20 80
5–9 30 120
10+ 40 160
The lower thresholds are based on empirical observations of worm numbers
associated with developmental deficits [15, 17]. The higher thresholds are a
more conservative value intended to reflect more serious clinical
consequences and to provide a lower bound to the estimate of morbidity
[15, 17]
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annual child-targeted treatment decreased with the inten-
sity of the transmission setting (Fig. 2).
Increasing the treatment frequency in children (bian-
nual child-targeted treatment) was projected to generate
only very small additional reductions in the prevalence
of morbidity and still did not affect a large proportion of
the overall burden (Fig. 2 and Table 2). In contrast,
annual community-wide treatment was projected to be
markedly more effective (317–748 % with a 75 % treat-
ment coverage of adults) in reducing the overall disease
burden (Table 2) and equivalent to biannual child-
targeted treatment in reducing the prevalence of mor-
bidity in children (Fig. 2).
The results in Fig. 2 pertain to the lower intensity
thresholds for morbidity (Table 1). When using the
higher intensity threshold the pre-control prevalence of
Fig. 2 Impact of different treatment strategies on the prevalence of morbidity in (a) the overall community, (b) Pre-SAC & SAC and (c) adults. Two different
transmission settings were explored; intermediate (R0 = 2.5), and high (R0 = 5) – as measured by the basic reproductive number (R0) [11]. Panels
a & d illustrate the overall mean number of worms across all ages, panels (b) & (e), the mean number of worms in children (Pre-SAC and SAC,
2–14 year olds), panels (c) & (f) the mean number of worms in adults (≥15 year olds). The different styled lines represent different treatment
strategies: solid – annual targeted treatment (Pre-SAC and SAC), dashed – biannual targeted treatment (Pre-SAC and SAC), and dotted –
annual community-wide treatment (Pre-SAC, SAC and adults). Individuals under two years of age were not eligible for treatment. The results
assume 80 % coverage per round of targeted age group(s), and 94.8 % treatment efficacy. The results employ the lower intensity thresholds for
morbidity (presented in Table 1). The corresponding results using the higher intensity threshold are presented in Additional file 1: Figure S2
Table 2 The number of morbidity case years averted for the three different strategies
Transmission
setting
Intensity thresholds for
morbidity
Annual child-targeted
treatment
Biannual child-targeted treatment
(a)
Community-wide treatment
(a)
Intermediate Lower 370 498 (35 %) 3136 (748 %)
Higher 2.4 3.2 (33 %) 9.8 (317 %)
High Lower 1230 1638 (33 %) 6075 (394 %)
Higher 93 135 (46 %) 583 (527 %)
aPercentage gain relative to annual child-targeted treatment. The effect is expressed in terms of morbidity case years prevented i.e. the number of years lived
with morbidity averted across the time horizon. For each year the effectiveness was calculated as the difference between the number of cases and the number
in absence of treatment. The results assume 75 % coverage per round of targeted age group(s), a total population size of 200,000, a discount rate of 3 %, and
94.8 % treatment efficacy. Analysis was conducted with a two-year implementation period and a 15-year time horizon (i.e. looking at the effect of two years of
treatment for 15 years). The intensity thresholds for morbidity are presented in Table 1
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morbidity was notably lower and was almost negligible
in the intermediate transmission setting (Additional file 1:
Figure S2). Though the number morbidity case-years
averted was sensitive to the assumed intensity thresholds
for morbidity, the notable relative impact of community-
wide treatment was robust (Table 2). The sensitivity of the
impact of community-wide treatment to the level of
coverage in adults is shown in Table 3. Even at a low
coverage of adults (35 %) community-wide treatment still
had a noteworthy impact on morbidity (Table 3) (between
168 and 339 % more than child-targeted treatment).
Cost-effectiveness of morbidity control
The cost-effectiveness of community-wide treatment in
terms of preventing morbidity was notably higher than
annual child-targeted treatment – even when assuming
it increases programme distribution costs (Table 4).
When assuming a low coverage of adults, the increases
in cost-effectiveness were lower for a given increase in
cost (Table 4). However, even when the coverage of
adults was as low as 35 %, the model projected an
increase in cost-effectiveness (with the exception of when
the increase in the cost per year was 200 % (Table 4)).
When using the higher intensity threshold for morbid-
ity (which corresponds to >160 worms in adults
(Table 1)), the relative increase in cost-effectiveness was
lower in intermediate transmission settings than for a
lower morbidity threshold because the prevalence of
these infections was so low in these settings (Table 2
and Additional file 1: Figure S2). Note that the results in
Table 4 only investigate the impact of two treatment
rounds, and therefore do not account for any potential
cost savings resulting from breaking transmission with
community-wide treatment – which would increase
cost-effectiveness even further.
Even when assuming that the drug efficacy was
lower than previously assumed (64.2 % versus 94.8 %),
community-wide treatment was still predicted to generate
notable benefits and therefore it appears that the general
conclusions are robust (Additional file 1: Figure S3).
Transmission control
Child-targeted treatment (either annual or biannual)
was not found to notably impact the overall level of
transmission; children are therefore likely to become
reinfected quickly after treatment from the adult reservoirs
of infection – even in intermediate transmission settings
(Fig. 3). In contrast, community-wide treatment greatly
reduces the rate of transmission (because the adults
have the majority of the overall worm burden (Fig. 1)).
Consequently, treating adults can also benefit the children
(Fig. 2) –as it reduces the level of transmission for everyone
(Fig. 3). This is the reason that annual community-wide
treatment is predicted to have a comparable impact on
heavy infections in children as biannual child-targeted
treatment (Fig. 2).
Feasibility of and timeframe for breaking transmission
The level of treatment coverage in adults was the major
determinant of the feasibility of eliminating hookworm
transmission (Fig. 4). The higher the level of transmis-
sion (measured by the R0), the harder elimination was
projected to be – both in terms of the necessary level of
coverage and the required number of annual rounds of
treatment to cross the transmission breakpoint [11]
(Fig. 4). For example, with an overall coverage of 75 % it
was projected to take three rounds to break transmission
in the intermediate (R0 = 2.5) transmission setting, and
nine rounds in the high (R0 = 5) (Fig. 4).
Total programme costs and cost savings
Community-wide treatment is projected to be able to
break transmission, permitting a shorter duration for the
treatment programme (Fig. 4). It is therefore possible for
it to generate cost savings, compared to the current
child-targeted treatment strategy – even when it notably
increases the annual distribution costs of the programme
(Fig. 5 and Table 5). The overall costs are the annual
costs times the number of years of treatment required to
cross the transmission breakpoint. The longer the time
horizon considered for the analysis, the greater the
Table 3 The sensitivity to the relative increase in the number of morbidity case years averted by annual community-wide treatment
to the level of coverage in adults
Community-wide treatment
Transmission setting Intensity thresholds for morbidity Adult coverage: 75 % Adult coverage: 55 % Adult coverage: 35 %
Intermediate Lower 749 % 520 % 339 %
Higher 317 % 258 % 203 %
High Lower 394 % 275 % 168 %
Higher 527 % 439 % 327 %
Percentage gain is relative to annual child-targeted treatment with a coverage of 75 %. The effect is expressed in terms of morbidity case years prevented i.e. the
number of years lived with morbidity averted across the time horizon. For each year the effectiveness was calculated as the difference between the number of
cases and the number in absence of treatment. Assumptions are as in Table 2
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potential cost savings of community-wide treatment
(Fig. 5 and Table 5). The higher the transmission setting,
the lower the potential cost savings of community-wide
treatment (Fig. 5 and Additional file 1: Table S2). As
expected, community-wide treatment was projected to
cost more than child-targeted treatment in these settings
when using a short time horizon (as this does not ac-
count for any longer-term cost saving given elimination
of transmission). The point at which community-wide
treatment becomes cost-saving was dependent on both
the assumed cost of community-wide treatment and the
employed time horizon (Fig. 5, Table 5 and Additional
file 1: Table S2).
For a given incease in cost, the chance of cost-savings
from comminity-wide treatment were smaller the lower
the level of coverage achivied in adults (Table 5) – though
were notable even if the coverage was relatively low (55 %)
(Table 4). When assuming the coverage of adults was
35 %, cost savings were projected to be unlikely without
long time horizons for the modelled setting (Table 4) [12].
Table 4 The increase in the cost-effectiveness of preventing morbidity when using annual community-wide versus child-targeted
treatment
Transmission
setting
Intensity
thresholds
for
morbidity
Relative increase in the distribution costs (total per year) of community-wide versus child-targeted treatment
+50 % +100 % +150 % +200 %
Coverage of adults: 75 %
Intermediate Lower +1397 % +649 % +399 % +274 %
Higher +534 % +217 % +111 % +59 %
High Lower +688 % +294 % +163 % +97 %
Higher +953 % +427 % +251 % +163 %
Coverage of adults: 35 %
Intermediate Lower +577 % +239 % +126 % +69 %
Higher +307 % +103 % +36 % +2 %
High Lower +236 % +68 % +12 % −16 %
Higher +554 % +227 % +118 % +63 %
The percentage increase compares the incremental relative cost and incremental benefit of community-wide treatment to that of annual child-targeted
treatment (75 % coverage of children). The benefit is expressed in terms of morbidity case years prevented i.e. the number of years lived with morbidity averted.
Assumptions are as in Table 2. As the results only investigate the impact of two treatment rounds they do not account for any potential cost savings resulting
from breaking transmission with community-wide treatment. Negative values are shown in bold i.e. community-wide treatment was not more cost-effective
Fig. 3 Impact of different treatment strategies on the overall rate of transmission. Force of infection: the mean number of incoming worms per
person per year (a metric for the level of on-going transmission within the model). Two different transmission settings were explored; intermediate
(R0 = 2.5), and high (R0 = 5) – as measured by the basic reproductive number (R0) [11]. The different styled lines represent different treatment strategies:
solid – annual targeted treatment (Pre-SAC and SAC), dashed – biannual targeted treatment (Pre-SAC and SAC), and dotted – annual community-wide
treatment (Pre-SAC, SAC and adults). Results assume 80 % coverage per round of target age group(s), and 94.8 % treatment efficacy. Individuals under
two years of age were not eligible for treatment
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When assuming a lower drug efficacy of 64.2 %, the
number of rounds required to break transmission was
higher (Additional file 1: Figure S4) and therefore cost-
savings was lower/less likely. With this pessimistic as-
sumption on efficacy, it was not possible to eliminate in
high transmission settings with MDA alone (Additional
file 1: Figure S4) and therefore no cost savings were pro-
jected in this scenario.
The projected timeframes for elimination and cost
savings were consistent when using a different parameter
for the strength of the density dependence in egg produc-
tion by female worms (Additional file 1: Table S3) and were
even more pronounced when using an alternative dataset
for the baseline age profile of infection intensity (particularly
for lower coverages) (Fig. 1 and Additional file 1: Table S4).
Discounting
The employed discount rate had a major impact on the po-
tential cost savings generated by reaching elimination
through community-wide treatment (Additional file 1: Table
S5). The higher the discount rate, the lower the potential
cost savings (as these savings occur in the future – illus-
trated by the gradient of the solid curve in Fig. 5). However,
even with a high discount rate of 6 %, community-wide
treatment could still generate notable cost savings (depend-
ing on the time horizon and transmission settings).
Fig. 4 Number of years of annual treatment to achieve elimination of hookworm as a function of coverage of children versus adults. Two
different transmission settings were explored; intermediate (R0 = 2.5), and high (R0 = 5)– as measured by the basic reproductive number (R0) [11].
Results assume a 94.8 % treatment efficacy. Pre-SAC and SAC, 2–14 year olds; and adults, ≥15 year olds. Individuals under two years of age were
not eligible for treatment. NA; Not achievable within 15 years of annual treatment
Fig. 5 Cumulative total cost of community-wide versus child-targeted treatment. Annual targeted treatment (Pre-SAC and SAC) and annual
community-wide treatment are represented by a solid and dashed line respectively. Costs were assumed to cease after elimination is achieved.
The coloured dotted lines represent a range of different values regarding the cost per year of distributing community-wide treatment relative to
child-targeted treatment. Two different transmission settings were explored; A) intermediate (R0 = 2.5), and B) high (R0 = 5) – as measured by the
basic reproductive number (R0) [11]. The results assume 75 % coverage per round of targeted age group(s), and 94.8 % treatment efficacy. Costs
were discounted at 3 % per year (resulting in the slope of the curve). The different vertical lines highlight the different employed time horizons.
Individuals under two years of age were not eligible for treatment
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Discussion
Morbidity control
Our projections indicate that the current STH control
strategy, which focuses on targeting children, is ineffect-
ive in reducing the overall burden of disease induced by
hookworm infection – though it is effective in the con-
text of controlling morbidity in children (Fig. 2). This
occurs because the burden of infection lies largely in
adults due to the rising burden of infection with age
(Fig. 1) [24]. Consequently, the disease burden is
projected to be higher in adults compared to children
(Fig. 2). This is important because hookworm is esti-
mated to be responsible for over 65 % of the DALYs lost
due to STH infections [1], and worldwide it is the sec-
ond leading cause of anaemia [2]. Our analyses show
that in order to control the overall disease burden of
hookworm with preventive chemotherapy, programmes
must include adults through community-wide treatment
(Fig. 2), which is projected to be notably more cost-
effective in terms of preventing morbidity (Table 4).
In areas with a STH prevalence greater than 50 %,
WHO guidelines recommend that treatment frequency
in children is increased to at least twice a year [3].
Though this would have a notable benefit for Ascaris
and Trichuris [8, 23], our calculations indicate that this
strategy was projected to generate only very small add-
itional reductions in both morbidity (Fig. 2), and the
level of overall transmission (Fig. 3) for hookworm
[Turner et al., ‘Analysis of the population-level impact of
co-administering ivermectin with albendazole or meben-
dazole for the control and elimination of Trichuris tri-
chiura’, submitted].
It is important to note that the motivation for focusing
on treating children for STH is in part due to the poten-
tial developmental consequences of infection in children
(though this is an area that needs more investigation
[25]) and in part due to the ease with which SAC can be
accessed through the school. Though the evidence that
intestinal worms directly interfere with productivity and
wage earning capacity in adults (reviewed in [26]) is cir-
cumstantial, many of the health consequences of hook-
worm (especially anaemia [27, 28]) have been proven to
affect productivity in working teenagers and adults [29].
Consequently, treating adults for hookworm could gen-
erate economic gains and accelerate economic develop-
ment in endemic countries.
Over the past decade, many areas may have received
community-wide treatment which impacts STH through
lymphatic filariasis control programmes (which also use
albendazole). Where the impacts of lymphatic filariasis
control programmes on STH have been measured the
impact on hookworm has been notable [30]. Another
important route for adult treatment is through the treat-
ment of women of reproductive age within other pro-
grammes – such as iron supplementation campaigns,
but the level of treatment coverage is typically uncertain.
Transmission control
Timeframe for elimination
Our projections indicate that targeting children alone
does not notably impact the overall level of hookworm
transmission (Fig. 3). Consequently, it is not possible to
break transmission with drug administration alone with-
out including the treatment of adults [8-10] (Fig. 4).
Table 5 The relative total cost of annual community-wide versus child-targeted treatment in an intermediate transmission setting
Relative increase in the distribution costs (total per year) of community-wide versus child-targeted treatment
+50 % +100 % +150 % +200 %
Time horizon
Coverage of adults: 75 %
20 years −71 % −62 % −52 % −43 %
35 years −80 % −74 % −67 % −60 %
50 years −83 % −78 % −72 % −67 %
Coverage of adults: 55 %
20 years −45 % −27 % −6 % +9 %
35 years −62 % −50 % −35 % −24 %
50 years −68 % −58 % −45 % −37 %
Coverage of adults: 35 %
20 years +1 % +4 % +68 % +101 %
35 years −30 % −7 % +16 % +39 %
50 years −41 % −23 % −3 % +16 %
The results assume an annual treatment strategy, 75 % treatment coverage in children, and 94.8 % treatment efficacy. Costs were discounted at 3 % per year.
Results in bold are where the total costs of community-wide treatment are higher than child-targeted treatment (i.e. it was not cost saving and has a higher
relative cost). Results for the higher transmission setting are shown in Additional file 1: Table S2
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These results are supported in part by a previous model-
ling study by Chan et al. [31], which investigated the
effect of various mixing patterns between children and
adults on the impact of hookworm treatment. Further-
more, in a recent field trial in an area with a low baseline
hookworm infection, two semi-annual community-wide
treatments with albendazole were enough to almost
completely eliminate hookworm [30], which as such
supports these model predictions. The level of treatment
coverage in adults was the major determinant of the
feasibility of eliminating hookworm transmission
(Fig. 4). This finding contrasts with the model projections
for Ascaris and Trichuris, where the coverage of children
is often the major determinate [8-10], Turner et al., ‘Ana-
lysis of the population-level impact of co-administering
ivermectin with albendazole or mebendazole for the control
and elimination of Trichuris trichiura’, submitted.
Cost savings
Due to the projected reductions in programme duration,
it is possible for community-wide treatment to generate
cost savings compared to the current child-targeted
strategy. The extent of these costing savings was sensitive
to the assumed increase in distribution costs when using
community-wide treatment and the achieved coverage of
adults (Table 5 and Additional file 1: Table S2). However,
even when assuming it increases the programme’s distri-
bution costs by 200 %, the analysis indicates potential cost
savings in intermediate transmission settings when achiev-
ing a moderate to high coverage of adults (Table 5).
The higher the transmission setting and lower the
coverage in adults, the lesser the possibility of cost sav-
ings from community-wide treatment (Fig. 5 and Table 5
and Additional file 1: Table S2). This occurs because the
duration of community-wide treatment required to
break transmission (Fig. 4), and therefore its total cost,
increases with the intensity of the transmission setting
(Fig. 5). However, it should be noted that these high
transmission settings would have a higher prevalence of
morbidity (Fig. 2). Therefore, though the cost savings of
community-wide treatment are more uncertain in these
settings, the benefits regarding morbidity and accelerat-
ing socioeconomic development will be more positive
(Fig. 2).
Costs of community-wide versus child-targeted treatment
Due to the absence of data, we calculated the distribution
costs of community-wide treatment as a relative increase
over the cost per year of child-targeted treatment. This re-
flects that the increase in cost for community-wide treat-
ment will vary in different settings (see Methods).
It should be noted that it is often not possible to sim-
ply separate the costs of treating adults versus children
– as they employ overlapping distribution systems [19].
For example, if many un-enrolled SAC or Pre-SAC are
treated in the community rather than at the school, it
would reduce the observed cost of community-based
treatment (changing the apparent cost of treating
adults). Consequently, the relative cost per treatment of
the different strategies will also be influenced by the
local demography (due to economies of scale) [19]. In
addition, there will be fixed costs (i.e. those which do
not depend on the number treated) shared between both
distribution methods. Consequently, expanding treat-
ment to target adults may generate economies of scale
for the school-based programme, lowering the cost per
treatment for children [19, 20, 32].
Better cost data will permit more detailed cost-
effectiveness analysis, using absolute and not relative costs
[19] and an understanding of how the costs may be influ-
enced by coverage.
Programmatic considerations of treating adults as well as
children
Since the 2012 London Declaration on NTDs [33], the
availability of donated drugs is no longer the major bar-
rier to achieving the current WHO 2020 goals for STH
control [34]. However, focus has now shifted to scaling
up the implementation of STH programmes [34].
Expanding treatment programmes to include adults will
require more programmatic resources and may not
always be practical – particularly in countries which are
struggling to achieve a high coverage of children. This
highlights the fact that expanding treatment to commu-
nities will require further international aid support.
However, experiences with lymphatic filariasis and oncho-
cerciasis control programmes which use community-wide
MDA clearly demonstrate that expansion is programmat-
ically feasible and can be highly successful [35].
It is important to note that adding a community drug
distributor (CDD) to treat adults would likely improve
coverage of children (as the CDD may reach unenrolled
children and Pre-SAC within the community more
effectively). Where resources are limited to permit the
expansion to community-wide treatment, a potential
solution could be to further encourage the treatment of
the parents of SAC within the school-based pro-
grammes. Ensuring the economic productivity of the
children’s parents may also reduce school dropout rates.
GSK currently donates 400 million albendazole tablets
each year for STH control [36]. Expanding programmes
to target adults would increase the number of drugs
doses needed considerably. This has important economic
implications for donation programmes. However, it is
important to acknowledge that the total amount of
drugs required for donation could potentially decrease
in the long term (due to the capacity to break transmis-
sion). Unfortunately, mebendazole is less effective against
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hookworm [14], so in this context programmes may
have to rely on albendazole alone.
A further important programmatic consideration of
treating continuously across entire communities is the
potential risk of drug resistance developing. Restricting
drug treatment to children creates a reservoir of un-
treated worms in adults that can effectively dilute any
resistant gene pool in children. This issue needs careful
monitoring with more research to define markers to
track via molecular epidemiological studies.
Limitations
Uncertainty still surrounds some aspects of hookworm
biology and epidemiology. Consequently there is also
uncertainty surrounding model structure and parameter
estimation (and how these may differ for the different
hookworm species). However, the results of this analysis
depend largely on the observed age profiles of infection
intensity and the observation that the adults harbour the
majority of the worms – which was found to be robust
across a range of different settings (Fig. 1a) and for both
hookworm species (Fig. 1b); with the assumed host dem-
ography used within the model (from Uganda) [8], the
proportion of worms harboured by adults was between
70 and 85 % for the different settings (Fig. 1). This range
is also supported by [37]. It should be noted that the
potential cost-savings were even more pronounced when
using an alternative dataset for the baseline age profile
of infection intensity (Fig. 1 and Additional file 1: Table
S4). They were also robust when changing the parameter
for the strength of the density dependence in egg pro-
duction by female worms (Additional file 1: Table S3).
Within the model, a worm burden above previously
established intensity thresholds (Table 1) was used as a
proxy for morbidity [15]. It should be acknowledged that
these thresholds (Table 1) are uncertain and are likely to
be influenced by a number of host specific factors [38, 39].
Furthermore, the thresholds were based on a study where
N. americanus was the predominant hookworm species
and may be too high for A. duodenale (which is associated
with higher rates of blood loss per worm) [16]. More
research is needed for statistical models that relate the
disease burden of hookworm to experience of infection
and the impact of treatment, to allow models to accurately
estimate a cost per DALY averted.
This analysis assumed that once hookworm transmission
is broken the costs of control stop immediately. However,
in reality, certifying elimination would require a period
of post-intervention surveillance with associated costs.
Furthermore, STH control programmes also target Ascaris
and Trichuris and therefore may need to be continued even
if hookworm is eliminated (though community-wide treat-
ment would also accelerate the timeframe for breaking
transmission for these infections as well [8, 9, 10]).
The model does not currently address the possibility
of systematic non-compliance. If a high proportion of
adults were systematically non-compliant, the timeframe
for elimination would be increased, reducing the poten-
tial cost savings of community-wide treatment (though
the general principles still apply).
Conclusions
Annual community-wide treatment is predicted to be mark-
edly more cost-effective in controlling both hookworm’s
disease burden and the level of on-going transmission.
Furthermore, because it is possible to break transmission
when using community-wide treatment (which reduces the
required programme duration), expanding programmes can
generate long term cost savings– even if it notably increases
the annual distribution costs of the programme when
achieving a moderate to high coverage of adults.
Although expanding programmes to target adults will
require greater programmatic resources and drug dona-
tions, the calculations highlight the notable benefits it can
generate and the importance of further considering this
strategy in any ongoing revisions of the treatment and
control guidelines for STH. These results highlight that
the current WHO guidelines, which recommend treating
all STH the same way (regardless of which age groups
have the highest burden), may lead to an inefficient use of
available drug donations and associated resources.
Additional file
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